283 related articles for article (PubMed ID: 34942397)
1. Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study.
Al-Shuhaib MBS; Hashim HO; Al-Shuhaib JMB
Comput Biol Med; 2022 Feb; 141():105155. PubMed ID: 34942397
[TBL] [Abstract][Full Text] [Related]
2. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
3. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
4. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
J Infect Public Health; 2021 Feb; 14(2):227-237. PubMed ID: 33493919
[TBL] [Abstract][Full Text] [Related]
6. Artecanin of
Al-Shuhaib MBS; Hashim HO; Al-Shuhaib JMB; Obayes DH
J Biomol Struct Dyn; 2023 Apr; 41(6):2355-2367. PubMed ID: 35067202
[TBL] [Abstract][Full Text] [Related]
7. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
[TBL] [Abstract][Full Text] [Related]
8. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
Lu J; Hou Y; Ge S; Wang X; Wang J; Hu T; Lv Y; He H; Wang C
Life Sci; 2021 Feb; 266():118889. PubMed ID: 33310043
[TBL] [Abstract][Full Text] [Related]
9. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
10. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry.
Zhang D; Hamdoun S; Chen R; Yang L; Ip CK; Qu Y; Li R; Jiang H; Yang Z; Chung SK; Liu L; Wong VKW
Pharmacol Res; 2021 Oct; 172():105820. PubMed ID: 34403732
[TBL] [Abstract][Full Text] [Related]
11.
Sharma P; Joshi T; Joshi T; Mathpal S; Maiti P; Nand M; Chandra S; Tamta S
J Biomol Struct Dyn; 2023 Feb; 41(2):646-658. PubMed ID: 34854365
[TBL] [Abstract][Full Text] [Related]
12. Plant derived active compounds as potential anti SARS-CoV-2 agents: an
Kashyap D; Jakhmola S; Tiwari D; Kumar R; Moorthy NSHN; Elangovan M; Brás NF; Jha HC
J Biomol Struct Dyn; 2022; 40(21):10629-10650. PubMed ID: 34225565
[TBL] [Abstract][Full Text] [Related]
13. Spike protein recognizer receptor ACE2 targeted identification of potential natural antiviral drug candidates against SARS-CoV-2.
Pokhrel S; Bouback TA; Samad A; Nur SM; Alam R; Abdullah-Al-Mamun M; Nain Z; Imon RR; Talukder MEK; Tareq MMI; Hossen MS; Karpiński TM; Ahammad F; Qadri I; Rahman MS
Int J Biol Macromol; 2021 Nov; 191():1114-1125. PubMed ID: 34592225
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
[TBL] [Abstract][Full Text] [Related]
15. Benzimidazole compound abrogates SARS-COV-2 receptor-binding domain (RBD)/ACE2 interaction In vitro.
Omotuyi O; Olatunji OM; Nash O; Oyinloye B; Soremekun O; Ijagbuji A; Fatumo S
Microb Pathog; 2023 Mar; 176():105994. PubMed ID: 36682669
[TBL] [Abstract][Full Text] [Related]
16. Repurposing immune boosting and anti-viral efficacy of
Dinata R; Nisa N; Arati C; Rasmita B; Uditraj C; Siddhartha R; Bhanushree B; Saeed-Ahmed L; Manikandan B; Bidanchi RM; Abinash G; Pori B; Khushboo M; Roy VK; Gurusubramanian G
J Biomol Struct Dyn; 2024; 42(1):43-81. PubMed ID: 37021347
[TBL] [Abstract][Full Text] [Related]
17. Corilagin and 1,3,6-Tri-
Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
[TBL] [Abstract][Full Text] [Related]
18. Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing molecular docking and molecular dynamics (MD) simulations.
Patel CN; Goswami D; Jaiswal DG; Parmar RM; Solanki HA; Pandya HA
J Mol Graph Model; 2021 Jun; 105():107874. PubMed ID: 33647752
[TBL] [Abstract][Full Text] [Related]
19. Prevention of SARS-CoV-2 cell entry: insight from
Gyebi GA; Adegunloye AP; Ibrahim IM; Ogunyemi OM; Afolabi SO; Ogunro OB
J Biomol Struct Dyn; 2022 Mar; 40(5):2121-2145. PubMed ID: 33089728
[TBL] [Abstract][Full Text] [Related]
20. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]